Abstract
Gene therapy is a newer approach in the twenty-first century which developed through the advancement of molecular biology and Human Genome Project. It has emerged as a key future strategy to cure both T1DM and T2DM. Gene therapy is accomplished by introducing DNA into cells, which can be carried out by several methods. Viral vectors (recombinant viruses) and non-viral vectors (naked DNA or DNA complexes) are mostly used in such process. Gene therapy usually targets the β cells of pancreatic islet or the insulin sensitivity toward the peripheral tissues. Introduction of DNA into target cells artificially should be stable and functional; it is also necessary that the target cells should accept the new DNA properly for natural reproduction function. Usually, ex vivo engineering and in vivo delivery methods are used in gene therapy. In ex vivo method, a cell will be isolated from the host and used as a transgene factory, and genetic manipulation is carried out in a laboratory. Cell expansion may or may not be part of it. This strategy is mostly employed in gene therapy. On the other hand, in vivo gene transfer method genetic modification is carried out in situ using vector-mediated delivery of genetic material into specific target organ. It is a difficult method due to selection of gene delivery vehicle that becomes an issue (Welsh 2000; Giannoukakis and Trucco 2003; Creusot and Fathman 2004; Bertolaso et al. 2010).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Anonymous. Anakinra improves glycaemia in type 2 diabetes. BMJ. 2007;334: 822.
Anonymous. DIAPREV-IT study of diabetes therapy Diamyd® receives further funding and will continue despite disappointing Phase III trial results. Immunotherapy. 2011;3:923–4.
Anonymous. Evotec announces update on DiaPep277®. 2014. Accessed from: http://www.evotec.com/article/en/Press-releases/Evotec-announces-update-on-DiaPep277/2653.
Apple J. Diapep277: slowing the progression of type 1 diabetes. 2012. Accessed on: http://asweetlife.org/feature/diapep277-slowing-the-progression-of-type-1-diabetes/.
Bertolaso M, Olsson J, Picardi A, Rakela J. Gene therapy and enhancement for diabetes (and other diseases): the multiplicity of considerations. Diabetes Metab Res Rev. 2010;26:520–4.
Bruni A, Gala-Lopez B, Pepper AR, Abualhassan NS, Shapiro AMJ. Islet cell transplantation for the treatment of type 1 diabetes: recent advances and future challenges. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. 2014;7:212–23.
Creusot RJ, Fathman CG. Gene therapy for type 1 diabetes: a novel approach for targeted treatment of autoimmunity. J Clin Invest. 2004;114:892–4.
Dayan C. Diabetes ‘vaccines’: can an injection prevent diabetes? Diabetes Voice. 2005;50:23–5.
Diamyd Medical. Diabetes clinical trials. 2014. Accessed from: http://www.diamyd.com/docs/trialsDiabetes.aspx?section=trials.
Giannoukakis N, Trucco M. Gene therapy technology applied to disorders of glucose metabolism: promise, achievements, and prospects. Biotechniques. 2003;35:122–45.
Goa C, Holscher C, Liu Y, Li L. GSK3: a key target for the development of novel treatments for type 2 diabetes mellitus and Alzheimer disease. Reviews Neurosci. 2012;23:1–11.
Goldfine AB, Fonseca V, Jablonski KA, et al. Salicylate (salsalate) in patients with type 2 diabetes: a randomized trial. Ann Intern Med. 2013;159:1–12.
Hinke SA. Diamyd, an alum-formulated recombinant human GAD65 for diabetes and the prevention of autoimmune diabetes. Curr Opin Mol Ther. 2008;10:1–10.
Hussain M, Theise ND. Stem-cell therapy for diabetes mellitus. Lancet. 2004;364:203–5.
Ito M, Fukuda S, Sakata S, Morinaga H, Ohta T. Pharmacological effects of JTT-551, a novel protein tyrosine phosphatase 1b inhibitor, in diet-induced obesity mice. Journal of Diabetes Research. 2014;2014:1–7.
Johnson TO, Ermolieff J, Jirousek MR. Protein tyrosine phosphatase 1B inhibitors for diabetes. Nat Rev Drug Discov. 2002;1:696–709.
Juang J. Islet transplantation: an update. Chang Gung Med J. 2004;27:1–15.
Kim DK, Gang GT, Ryu D, et al. Inverse agonist of nuclear receptor ERRγ mediates antidiabetic effect through inhibition of hepatic gluconeogenesis. Diabetes. 2013;62:3093–102.
Larsen CM, Faulenbach M, Vaag A. Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes. Diabetes Care. 2009;32:1663–8.
Larsen TM, Toubro S, van Baak MA, et al. Effect of a 28-d treatment with L-796568, a novel beta(3)-adrenergic receptor agonist, on energy expenditure and body composition in obese men. American Journal of Clinical Nutrition. 2002;76:780–8.
Li M, Ikehara S. Bone marrow stem cell as a potential treatment for diabetes. Journal of Diabetes Research. 2013;2013:1–5.
McCall MD, Tosa C, Baetge EE, Shapiro AMJ. Are stem cells a cure for diabetes? Clin Sci. 2010;118:87–97.
Merani S, Shapiro AMJ. Current status of pancreatic islet transplantation. Clin Sci. 2006;110:611–25.
NDIC. Pancreatic Islet Transplantation. 2014. Accessed from: http://diabetes.niddk.nih.gov/dm/pubs/pancreaticislet/.
Ong SL, Gravante G, Pollard CA, et al. Total pancreatectomy with islet autotransplantation: an overview. HPB. 2009;11:613–21.
Patel KP, Joshi HM, Majumdar FD, Patel VJ. Newer approaches in the treatment of diabetes mellitus. NHL Journal of Medical Sciences. 2013;2:6–11.
Raz I, Ziegler AG, Linn T, et al. Treatment of recent-onset type 1 diabetic patients with DiaPep277: results of a double-blind, placebo- controlled, randomized phase 3 trial. Diabetes Care. 2014;37:1392–400.
Rother KI, Harlan DM. Challenges facing islet transplantation for the treatment of type 1 diabetes mellitus. Journal of Clinical Investigation. 2004;114:877–83.
Sameer M, Balasubramanyam M, Mohan V. Stem cells and diabetes. Curr Sci. 2006;91:1158–65.
Wagman AS, Johnson KW, Bussiere DE. Discovery and development of GSK3 inhibitors for the treatment of type 2 diabetes. Curr Pharm Des. 2004;10:1105–37.
Weir G. Do stem cells hold the key to a future cure for diabetes? DiabetesVoice. 2008;53:29–31.
Welsh N. Prospects for gene therapy of diabetes mellitus. Gene Ther. 2000;7:181–2.
Yang L. Liver stem cell-derived h-cell surrogates for treatment of type 1 diabetes. Autoimmun Rev. 2006;5:409–13.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer Science+Business Media Singapore
About this chapter
Cite this chapter
Sen, S., Chakraborty, R., De, B. (2016). Recent Developments in Diabetes Therapy. In: Diabetes Mellitus in 21st Century. Springer, Singapore. https://doi.org/10.1007/978-981-10-1542-7_12
Download citation
DOI: https://doi.org/10.1007/978-981-10-1542-7_12
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-10-1541-0
Online ISBN: 978-981-10-1542-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)